Published in Mov Disord on July 01, 1994
Treatment of advanced Parkinson's disease. Parkinsons Dis (2011) 0.79
Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. Eur J Clin Pharmacol (2017) 0.75
Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication. J Mov Disord (2017) 0.75
Soluble and controlled-release preparations of levodopa: do we really need them? J Neurol (2010) 0.75
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol (1998) 9.33
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
A plan for 'responsible national health insurance'. Health Aff (Millwood) (1991) 2.52
Aerobic endurance training improves soccer performance. Med Sci Sports Exerc (2001) 2.34
Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology (1983) 2.20
Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke (2001) 2.15
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology (1975) 1.96
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology (1998) 1.96
Strength and endurance of elite soccer players. Med Sci Sports Exerc (1998) 1.94
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol (1996) 1.88
Degradation of alpha-synuclein by proteasome. J Biol Chem (1999) 1.87
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry (1992) 1.76
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol (2003) 1.75
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord (1998) 1.63
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Cortical abnormalities in Alzheimer's disease. Ann Neurol (1984) 1.57
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science (1987) 1.49
L-Dopa-induced release of cerebral monoamines. Science (1970) 1.47
Strong correlation of maximal squat strength with sprint performance and vertical jump height in elite soccer players. Br J Sports Med (2004) 1.47
Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther (1970) 1.46
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology (2003) 1.46
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology (1997) 1.46
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology (1997) 1.42
Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology (1992) 1.41
Structural brain changes after 4 wk of unilateral strength training of the lower limb. J Appl Physiol (1985) (2013) 1.40
Milacemide therapy for Parkinson's disease. Mov Disord (1993) 1.38
Metabolism of tyramine-3H and octopamine-3H by rat brain. Biochem Pharmacol (1969) 1.35
Clinical and electroencephalographic manifestations of vascular lesions of the pons. Neurology (1968) 1.30
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol (1987) 1.29
Towards a behavioral typology of Alzheimer's patients. J Clin Exp Neuropsychol (1986) 1.29
Stimulus-induced release of substances from olfactory bulb using the push-pull cannula. Nature (1968) 1.26
Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci (1999) 1.25
Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription. J Biol Chem (2000) 1.25
Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J Neurochem (2001) 1.21
PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Hum Mol Genet (1999) 1.21
Targeting of marrow-derived astrocytes to the ischemic brain. Neuroreport (1999) 1.21
Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology (1988) 1.19
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol (1988) 1.19
Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience (2000) 1.17
Racial variation in initial stroke severity. Stroke (2000) 1.17
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology (2001) 1.15
Physiological adaptations to soccer specific endurance training in professional youth soccer players. Br J Sports Med (2005) 1.14
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol (1990) 1.13
Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med (2002) 1.12
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology (1976) 1.11
Magnetic resonance imaging in Huntington disease. AJNR Am J Neuroradiol (1986) 1.10
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol (1988) 1.10
Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology (1996) 1.10
Impaired recognition of the goal location during spatial navigation in rats with hippocampal lesions. J Neurosci (2001) 1.10
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology (1992) 1.08
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol (1987) 1.07
Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol (1984) 1.07
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res (1994) 1.05
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol (1999) 1.05
Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J (2004) 1.05
Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol (1989) 1.04
Structural and functional studies of Gilles de la Tourette syndrome. Rev Neurol (Paris) (1986) 1.04
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord (2001) 1.03
Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet (1970) 1.03
Effect of ions on stimulus-induced release of amino acids from mammalian brain slices. J Neurochem (1969) 1.03
The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology (1993) 1.03
Living-related kidney donors: a multicenter study of donor education, socioeconomic adjustment, and rehabilitation. Am J Kidney Dis (1986) 1.02
BDNF synthesis in spiral ganglion neurons is constitutive and CREB-dependent. Hear Res (2001) 1.02
Frontal lobe function in progressive supranuclear palsy. Arch Neurol (1990) 1.02
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology (2002) 1.02
The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology (2002) 1.02
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans. Nature (1974) 1.02
Lactate threshold responses to a season of professional British youth soccer. Br J Sports Med (2005) 1.02
Soccer specific testing of maximal oxygen uptake. J Sports Med Phys Fitness (2003) 1.01
Aging attenuates vascular and metabolic plasticity but does not limit improvement in muscle VO(2) max. Am J Physiol Heart Circ Physiol (2003) 1.00
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Mov Disord (1992) 1.00
Serotonin and central nervous system function. Annu Rev Pharmacol (1973) 0.99
Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem (2001) 0.99
Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry (1991) 0.98
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther (1999) 0.98
Spontaneous spinal epidural haemorrhage: good results after early treatment. J Neurol Neurosurg Psychiatry (1975) 0.98
Coordination, the determinant of velocity specificity? J Appl Physiol (1985) (1996) 0.98
Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology (1970) 0.98
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology (1999) 0.97
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol (2005) 0.97
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology (2003) 0.97
Neurohumoral mechanisms in the brain slice. Adv Pharmacol Chemother (1970) 0.97
Effect of L-DOPA on depression. Lancet (1969) 0.97
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet (1971) 0.96
A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides (1985) 0.96
PQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domain. Biochem Biophys Res Commun (2000) 0.96
Muscimol: GABA agonist therapy in schizophrenia. Am J Psychiatry (1978) 0.95
ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene. J Biol Chem (2000) 0.95